

Global Interleukin Inhibitors for Psoriasis Market Growth 2024-2030

<https://marketpublishers.com/r/GF1EC59DCD5BEN.html>

Date: November 2024

Pages: 107

Price: US\$ 3,660.00 (Single User License)

ID: GF1EC59DCD5BEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Interleukin inhibitors for psoriasis refer to a class of biologic medications that specifically target and inhibit interleukins. Psoriasis is characterized by an overactive immune response that leads to excessive production of cytokines such as interleukin-12 (IL-12), interleukin-23 (IL-23), and interleukin-17A (IL-17A), among others. IL inhibitors work by blocking these specific interleukins or their receptors, thereby interrupting the inflammatory cascade responsible for the skin lesions and systemic symptoms associated with psoriasis.

The global Interleukin Inhibitors for Psoriasis market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "Interleukin Inhibitors for Psoriasis Industry Forecast" looks at past sales and reviews total world Interleukin Inhibitors for Psoriasis sales in 2023, providing a comprehensive analysis by region and market sector of projected Interleukin Inhibitors for Psoriasis sales for 2024 through 2030. With Interleukin Inhibitors for Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Interleukin Inhibitors for Psoriasis industry.

This Insight Report provides a comprehensive analysis of the global Interleukin Inhibitors for Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with

a focus on Interleukin Inhibitors for Psoriasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Interleukin Inhibitors for Psoriasis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Interleukin Inhibitors for Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Interleukin Inhibitors for Psoriasis.

United States market for Interleukin Inhibitors for Psoriasis is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Interleukin Inhibitors for Psoriasis is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Interleukin Inhibitors for Psoriasis is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Interleukin Inhibitors for Psoriasis players cover Dalian Yawei Pharmaceutical, Janssen Biotech, Teva, UCB, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Interleukin Inhibitors for Psoriasis market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Interleukin-8 Inhibitors

Interleukin-12 Inhibitors

Interleukin-17 Inhibitors

Interleukin-23 Inhibitors

Other

Segmentation by Application:

Hospital and Clinic

Retail Pharmacies

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Dalian Yawei Pharmaceutical

Janssen Biotech

Teva

UCB

Eli Lilly

Novartis

Ortho Dermatologics

LEO Pharma

Kyowa Kirin

Samsung Bioepis

Sun Pharma

China Medical System

Almirall

AbbVie Biotechnology

Key Questions Addressed in this Report

What is the 10-year outlook for the global Interleukin Inhibitors for Psoriasis market?

What factors are driving Interleukin Inhibitors for Psoriasis market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Interleukin Inhibitors for Psoriasis market opportunities vary by end market size?

How does Interleukin Inhibitors for Psoriasis break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Interleukin Inhibitors for Psoriasis Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Interleukin Inhibitors for Psoriasis by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Interleukin Inhibitors for Psoriasis by Country/Region, 2019, 2023 & 2030
- 2.2 Interleukin Inhibitors for Psoriasis Segment by Type
 - 2.2.1 Interleukin-8 Inhibitors
 - 2.2.2 Interleukin-12 Inhibitors
 - 2.2.3 Interleukin-17 Inhibitors
 - 2.2.4 Interleukin-23 Inhibitors
 - 2.2.5 Other
- 2.3 Interleukin Inhibitors for Psoriasis Sales by Type
 - 2.3.1 Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Interleukin Inhibitors for Psoriasis Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Interleukin Inhibitors for Psoriasis Sale Price by Type (2019-2024)
- 2.4 Interleukin Inhibitors for Psoriasis Segment by Application
 - 2.4.1 Hospital and Clinic
 - 2.4.2 Retail Pharmacies
 - 2.4.3 Other
- 2.5 Interleukin Inhibitors for Psoriasis Sales by Application
 - 2.5.1 Global Interleukin Inhibitors for Psoriasis Sale Market Share by Application

(2019-2024)

2.5.2 Global Interleukin Inhibitors for Psoriasis Revenue and Market Share by Application (2019-2024)

2.5.3 Global Interleukin Inhibitors for Psoriasis Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Interleukin Inhibitors for Psoriasis Breakdown Data by Company

3.1.1 Global Interleukin Inhibitors for Psoriasis Annual Sales by Company (2019-2024)

3.1.2 Global Interleukin Inhibitors for Psoriasis Sales Market Share by Company (2019-2024)

3.2 Global Interleukin Inhibitors for Psoriasis Annual Revenue by Company (2019-2024)

3.2.1 Global Interleukin Inhibitors for Psoriasis Revenue by Company (2019-2024)

3.2.2 Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Company (2019-2024)

3.3 Global Interleukin Inhibitors for Psoriasis Sale Price by Company

3.4 Key Manufacturers Interleukin Inhibitors for Psoriasis Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Interleukin Inhibitors for Psoriasis Product Location Distribution

3.4.2 Players Interleukin Inhibitors for Psoriasis Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR INTERLEUKIN INHIBITORS FOR PSORIASIS BY GEOGRAPHIC REGION

4.1 World Historic Interleukin Inhibitors for Psoriasis Market Size by Geographic Region (2019-2024)

4.1.1 Global Interleukin Inhibitors for Psoriasis Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Interleukin Inhibitors for Psoriasis Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Interleukin Inhibitors for Psoriasis Market Size by Country/Region (2019-2024)

4.2.1 Global Interleukin Inhibitors for Psoriasis Annual Sales by Country/Region

(2019-2024)

4.2.2 Global Interleukin Inhibitors for Psoriasis Annual Revenue by Country/Region

(2019-2024)

4.3 Americas Interleukin Inhibitors for Psoriasis Sales Growth

4.4 APAC Interleukin Inhibitors for Psoriasis Sales Growth

4.5 Europe Interleukin Inhibitors for Psoriasis Sales Growth

4.6 Middle East & Africa Interleukin Inhibitors for Psoriasis Sales Growth

5 AMERICAS

5.1 Americas Interleukin Inhibitors for Psoriasis Sales by Country

5.1.1 Americas Interleukin Inhibitors for Psoriasis Sales by Country (2019-2024)

5.1.2 Americas Interleukin Inhibitors for Psoriasis Revenue by Country (2019-2024)

5.2 Americas Interleukin Inhibitors for Psoriasis Sales by Type (2019-2024)

5.3 Americas Interleukin Inhibitors for Psoriasis Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Interleukin Inhibitors for Psoriasis Sales by Region

6.1.1 APAC Interleukin Inhibitors for Psoriasis Sales by Region (2019-2024)

6.1.2 APAC Interleukin Inhibitors for Psoriasis Revenue by Region (2019-2024)

6.2 APAC Interleukin Inhibitors for Psoriasis Sales by Type (2019-2024)

6.3 APAC Interleukin Inhibitors for Psoriasis Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Interleukin Inhibitors for Psoriasis by Country

7.1.1 Europe Interleukin Inhibitors for Psoriasis Sales by Country (2019-2024)

- 7.1.2 Europe Interleukin Inhibitors for Psoriasis Revenue by Country (2019-2024)
- 7.2 Europe Interleukin Inhibitors for Psoriasis Sales by Type (2019-2024)
- 7.3 Europe Interleukin Inhibitors for Psoriasis Sales by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Interleukin Inhibitors for Psoriasis by Country
 - 8.1.1 Middle East & Africa Interleukin Inhibitors for Psoriasis Sales by Country (2019-2024)
 - 8.1.2 Middle East & Africa Interleukin Inhibitors for Psoriasis Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Interleukin Inhibitors for Psoriasis Sales by Type (2019-2024)
- 8.3 Middle East & Africa Interleukin Inhibitors for Psoriasis Sales by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Interleukin Inhibitors for Psoriasis
- 10.3 Manufacturing Process Analysis of Interleukin Inhibitors for Psoriasis
- 10.4 Industry Chain Structure of Interleukin Inhibitors for Psoriasis

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Interleukin Inhibitors for Psoriasis Distributors

11.3 Interleukin Inhibitors for Psoriasis Customer

12 WORLD FORECAST REVIEW FOR INTERLEUKIN INHIBITORS FOR PSORIASIS BY GEOGRAPHIC REGION

12.1 Global Interleukin Inhibitors for Psoriasis Market Size Forecast by Region

12.1.1 Global Interleukin Inhibitors for Psoriasis Forecast by Region (2025-2030)

12.1.2 Global Interleukin Inhibitors for Psoriasis Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Interleukin Inhibitors for Psoriasis Forecast by Type (2025-2030)

12.7 Global Interleukin Inhibitors for Psoriasis Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Dalian Yawei Pharmaceutical

13.1.1 Dalian Yawei Pharmaceutical Company Information

13.1.2 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.1.3 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Dalian Yawei Pharmaceutical Main Business Overview

13.1.5 Dalian Yawei Pharmaceutical Latest Developments

13.2 Janssen Biotech

13.2.1 Janssen Biotech Company Information

13.2.2 Janssen Biotech Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.2.3 Janssen Biotech Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Janssen Biotech Main Business Overview

13.2.5 Janssen Biotech Latest Developments

13.3 Teva

13.3.1 Teva Company Information

13.3.2 Teva Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.3.3 Teva Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross

Margin (2019-2024)

13.3.4 Teva Main Business Overview

13.3.5 Teva Latest Developments

13.4 UCB

13.4.1 UCB Company Information

13.4.2 UCB Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.4.3 UCB Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross

Margin (2019-2024)

13.4.4 UCB Main Business Overview

13.4.5 UCB Latest Developments

13.5 Eli Lilly

13.5.1 Eli Lilly Company Information

13.5.2 Eli Lilly Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.5.3 Eli Lilly Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross

Margin (2019-2024)

13.5.4 Eli Lilly Main Business Overview

13.5.5 Eli Lilly Latest Developments

13.6 Novartis

13.6.1 Novartis Company Information

13.6.2 Novartis Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.6.3 Novartis Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross

Margin (2019-2024)

13.6.4 Novartis Main Business Overview

13.6.5 Novartis Latest Developments

13.7 Ortho Dermatologics

13.7.1 Ortho Dermatologics Company Information

13.7.2 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.7.3 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Ortho Dermatologics Main Business Overview

13.7.5 Ortho Dermatologics Latest Developments

13.8 LEO Pharma

13.8.1 LEO Pharma Company Information

13.8.2 LEO Pharma Interleukin Inhibitors for Psoriasis Product Portfolios and

Specifications

13.8.3 LEO Pharma Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 LEO Pharma Main Business Overview

13.8.5 LEO Pharma Latest Developments

13.9 Kyowa Kirin

13.9.1 Kyowa Kirin Company Information

13.9.2 Kyowa Kirin Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.9.3 Kyowa Kirin Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Kyowa Kirin Main Business Overview

13.9.5 Kyowa Kirin Latest Developments

13.10 Samsung Bioepis

13.10.1 Samsung Bioepis Company Information

13.10.2 Samsung Bioepis Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.10.3 Samsung Bioepis Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Samsung Bioepis Main Business Overview

13.10.5 Samsung Bioepis Latest Developments

13.11 Sun Pharma

13.11.1 Sun Pharma Company Information

13.11.2 Sun Pharma Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.11.3 Sun Pharma Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.11.4 Sun Pharma Main Business Overview

13.11.5 Sun Pharma Latest Developments

13.12 China Medical System

13.12.1 China Medical System Company Information

13.12.2 China Medical System Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.12.3 China Medical System Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.12.4 China Medical System Main Business Overview

13.12.5 China Medical System Latest Developments

13.13 Almirall

13.13.1 Almirall Company Information

13.13.2 Almirall Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.13.3 Almirall Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.13.4 Almirall Main Business Overview

13.13.5 Almirall Latest Developments

13.14 AbbVie Biotechnology

13.14.1 AbbVie Biotechnology Company Information

13.14.2 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

13.14.3 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.14.4 AbbVie Biotechnology Main Business Overview

13.14.5 AbbVie Biotechnology Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Interleukin Inhibitors for Psoriasis Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Interleukin Inhibitors for Psoriasis Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Interleukin-8 Inhibitors

Table 4. Major Players of Interleukin-12 Inhibitors

Table 5. Major Players of Interleukin-17 Inhibitors

Table 6. Major Players of Interleukin-23 Inhibitors

Table 7. Major Players of Other

Table 8. Global Interleukin Inhibitors for Psoriasis Sales byType (2019-2024) & (K Units)

Table 9. Global Interleukin Inhibitors for Psoriasis Sales Market Share byType (2019-2024)

Table 10. Global Interleukin Inhibitors for Psoriasis Revenue byType (2019-2024) & (\$ million)

Table 11. Global Interleukin Inhibitors for Psoriasis Revenue Market Share byType (2019-2024)

Table 12. Global Interleukin Inhibitors for Psoriasis Sale Price byType (2019-2024) & (US\$/Unit)

Table 13. Global Interleukin Inhibitors for Psoriasis Sale by Application (2019-2024) &

(K Units)

Table 14. Global Interleukin Inhibitors for Psoriasis Sale Market Share by Application (2019-2024)

Table 15. Global Interleukin Inhibitors for Psoriasis Revenue by Application (2019-2024) & (\$ million)

Table 16. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2019-2024)

Table 17. Global Interleukin Inhibitors for Psoriasis Sale Price by Application (2019-2024) & (US\$/Unit)

Table 18. Global Interleukin Inhibitors for Psoriasis Sales by Company (2019-2024) & (K Units)

Table 19. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Company (2019-2024)

Table 20. Global Interleukin Inhibitors for Psoriasis Revenue by Company (2019-2024) & (\$ millions)

Table 21. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Company (2019-2024)

Table 22. Global Interleukin Inhibitors for Psoriasis Sale Price by Company (2019-2024) & (US\$/Unit)

Table 23. Key Manufacturers Interleukin Inhibitors for Psoriasis Producing Area Distribution and Sales Area

Table 24. Players Interleukin Inhibitors for Psoriasis Products Offered

Table 25. Interleukin Inhibitors for Psoriasis Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. Global Interleukin Inhibitors for Psoriasis Sales by Geographic Region (2019-2024) & (K Units)

Table 29. Global Interleukin Inhibitors for Psoriasis Sales Market Share Geographic Region (2019-2024)

Table 30. Global Interleukin Inhibitors for Psoriasis Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 31. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Geographic Region (2019-2024)

Table 32. Global Interleukin Inhibitors for Psoriasis Sales by Country/Region (2019-2024) & (K Units)

Table 33. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Country/Region (2019-2024)

Table 34. Global Interleukin Inhibitors for Psoriasis Revenue by Country/Region

(2019-2024) & (\$ millions)

Table 35. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Country/Region (2019-2024)

Table 36. Americas Interleukin Inhibitors for Psoriasis Sales by Country (2019-2024) & (K Units)

Table 37. Americas Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2019-2024)

Table 38. Americas Interleukin Inhibitors for Psoriasis Revenue by Country (2019-2024) & (\$ millions)

Table 39. Americas Interleukin Inhibitors for Psoriasis Sales byType (2019-2024) & (K Units)

Table 40. Americas Interleukin Inhibitors for Psoriasis Sales by Application (2019-2024) & (K Units)

Table 41. APAC Interleukin Inhibitors for Psoriasis Sales by Region (2019-2024) & (K Units)

Table 42. APAC Interleukin Inhibitors for Psoriasis Sales Market Share by Region (2019-2024)

Table 43. APAC Interleukin Inhibitors for Psoriasis Revenue by Region (2019-2024) & (\$ millions)

Table 44. APAC Interleukin Inhibitors for Psoriasis Sales byType (2019-2024) & (K Units)

Table 45. APAC Interleukin Inhibitors for Psoriasis Sales by Application (2019-2024) & (K Units)

Table 46. Europe Interleukin Inhibitors for Psoriasis Sales by Country (2019-2024) & (K Units)

Table 47. Europe Interleukin Inhibitors for Psoriasis Revenue by Country (2019-2024) & (\$ millions)

Table 48. Europe Interleukin Inhibitors for Psoriasis Sales byType (2019-2024) & (K Units)

Table 49. Europe Interleukin Inhibitors for Psoriasis Sales by Application (2019-2024) & (K Units)

Table 50. Middle East & Africa Interleukin Inhibitors for Psoriasis Sales by Country (2019-2024) & (K Units)

Table 51. Middle East & Africa Interleukin Inhibitors for Psoriasis Revenue Market Share by Country (2019-2024)

Table 52. Middle East & Africa Interleukin Inhibitors for Psoriasis Sales byType (2019-2024) & (K Units)

Table 53. Middle East & Africa Interleukin Inhibitors for Psoriasis Sales by Application (2019-2024) & (K Units)

Table 54. Key Market Drivers & Growth Opportunities of Interleukin Inhibitors for Psoriasis

Table 55. Key Market Challenges & Risks of Interleukin Inhibitors for Psoriasis

Table 56. Key Industry Trends of Interleukin Inhibitors for Psoriasis

Table 57. Interleukin Inhibitors for Psoriasis Raw Material

Table 58. Key Suppliers of Raw Materials

Table 59. Interleukin Inhibitors for Psoriasis Distributors List

Table 60. Interleukin Inhibitors for Psoriasis Customer List

Table 61. Global Interleukin Inhibitors for Psoriasis Sales Forecast by Region (2025-2030) & (K Units)

Table 62. Global Interleukin Inhibitors for Psoriasis Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 63. Americas Interleukin Inhibitors for Psoriasis Sales Forecast by Country (2025-2030) & (K Units)

Table 64. Americas Interleukin Inhibitors for Psoriasis Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 65. APAC Interleukin Inhibitors for Psoriasis Sales Forecast by Region (2025-2030) & (K Units)

Table 66. APAC Interleukin Inhibitors for Psoriasis Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 67. Europe Interleukin Inhibitors for Psoriasis Sales Forecast by Country (2025-2030) & (K Units)

Table 68. Europe Interleukin Inhibitors for Psoriasis Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 69. Middle East & Africa Interleukin Inhibitors for Psoriasis Sales Forecast by Country (2025-2030) & (K Units)

Table 70. Middle East & Africa Interleukin Inhibitors for Psoriasis Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 71. Global Interleukin Inhibitors for Psoriasis Sales Forecast by Type (2025-2030) & (K Units)

Table 72. Global Interleukin Inhibitors for Psoriasis Revenue Forecast by Type (2025-2030) & (\$ millions)

Table 73. Global Interleukin Inhibitors for Psoriasis Sales Forecast by Application (2025-2030) & (K Units)

Table 74. Global Interleukin Inhibitors for Psoriasis Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 75. Dalian Yawei Pharmaceutical Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 76. Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Product

Portfolios and Specifications

Table 77. Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 78. Dalian Yawei Pharmaceutical Main Business

Table 79. Dalian Yawei Pharmaceutical Latest Developments

Table 80. Janssen Biotech Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 81. Janssen Biotech Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 82. Janssen Biotech Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 83. Janssen Biotech Main Business

Table 84. Janssen Biotech Latest Developments

Table 85. Teva Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 86. Teva Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 87. Teva Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 88. Teva Main Business

Table 89. Teva Latest Developments

Table 90. UCB Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 91. UCB Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 92. UCB Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 93. UCB Main Business

Table 94. UCB Latest Developments

Table 95. Eli Lilly Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 96. Eli Lilly Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 97. Eli Lilly Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 98. Eli Lilly Main Business

Table 99. Eli Lilly Latest Developments

Table 100. Novartis Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 101. Novartis Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 102. Novartis Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 103. Novartis Main Business

Table 104. Novartis Latest Developments

Table 105. Ortho Dermatologics Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 106. Ortho Dermatologics Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 107. Ortho Dermatologics Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 108. Ortho Dermatologics Main Business

Table 109. Ortho Dermatologics Latest Developments

Table 110. LEO Pharma Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 111. LEO Pharma Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 112. LEO Pharma Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 113. LEO Pharma Main Business

Table 114. LEO Pharma Latest Developments

Table 115. Kyowa Kirin Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 116. Kyowa Kirin Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 117. Kyowa Kirin Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 118. Kyowa Kirin Main Business

Table 119. Kyowa Kirin Latest Developments

Table 120. Samsung Bioepis Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 121. Samsung Bioepis Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 122. Samsung Bioepis Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 123. Samsung Bioepis Main Business

Table 124. Samsung Bioepis Latest Developments

Table 125. Sun Pharma Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 126. Sun Pharma Interleukin Inhibitors for Psoriasis Product Portfolios and

Specifications

Table 127. Sun Pharma Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 128. Sun Pharma Main Business

Table 129. Sun Pharma Latest Developments

Table 130. China Medical System Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 131. China Medical System Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 132. China Medical System Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 133. China Medical System Main Business

Table 134. China Medical System Latest Developments

Table 135. Almirall Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 136. Almirall Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 137. Almirall Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 138. Almirall Main Business

Table 139. Almirall Latest Developments

Table 140. AbbVie Biotechnology Basic Information, Interleukin Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 141. AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Product Portfolios and Specifications

Table 142. AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 143. AbbVie Biotechnology Main Business

Table 144. AbbVie Biotechnology Latest Developments

LIST OFFIGURES

Figure 1. Picture of Interleukin Inhibitors for Psoriasis

Figure 2. Interleukin Inhibitors for Psoriasis Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Interleukin Inhibitors for Psoriasis Sales Growth Rate 2019-2030 (K Units)

Figure 7. Global Interleukin Inhibitors for Psoriasis Revenue Growth Rate 2019-2030 (\$ millions)

Figure 8. Interleukin Inhibitors for Psoriasis Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 9. Interleukin Inhibitors for Psoriasis Sales Market Share by Country/Region (2023)

Figure 10. Interleukin Inhibitors for Psoriasis Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 11. Product Picture of Interleukin-8 Inhibitors

Figure 12. Product Picture of Interleukin-12 Inhibitors

Figure 13. Product Picture of Interleukin-17 Inhibitors

Figure 14. Product Picture of Interleukin-23 Inhibitors

Figure 15. Product Picture of Other

Figure 16. Global Interleukin Inhibitors for Psoriasis Sales Market Share byType in 2023

Figure 17. Global Interleukin Inhibitors for Psoriasis Revenue Market Share byType (2019-2024)

Figure 18. Interleukin Inhibitors for Psoriasis Consumed in Hospital and Clinic

Figure 19. Global Interleukin Inhibitors for Psoriasis Market: Hospital and Clinic (2019-2024) & (K Units)

Figure 20. Interleukin Inhibitors for Psoriasis Consumed in Retail Pharmacies

Figure 21. Global Interleukin Inhibitors for Psoriasis Market: Retail Pharmacies (2019-2024) & (K Units)

Figure 22. Interleukin Inhibitors for Psoriasis Consumed in Other

Figure 23. Global Interleukin Inhibitors for Psoriasis Market: Other (2019-2024) & (K Units)

Figure 24. Global Interleukin Inhibitors for Psoriasis Sale Market Share by Application (2023)

Figure 25. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application in 2023

Figure 26. Interleukin Inhibitors for Psoriasis Sales by Company in 2023 (K Units)

Figure 27. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Company in 2023

Figure 28. Interleukin Inhibitors for Psoriasis Revenue by Company in 2023 (\$ millions)

Figure 29. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Company in 2023

Figure 30. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Geographic Region (2019-2024)

Figure 31. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Geographic Region in 2023

Figure 32. Americas Interleukin Inhibitors for Psoriasis Sales 2019-2024 (K Units)

Figure 33. Americas Interleukin Inhibitors for Psoriasis Revenue 2019-2024 (\$ millions)

Figure 34. APAC Interleukin Inhibitors for Psoriasis Sales 2019-2024 (K Units)

Figure 35. APAC Interleukin Inhibitors for Psoriasis Revenue 2019-2024 (\$ millions)

Figure 36. Europe Interleukin Inhibitors for Psoriasis Sales 2019-2024 (K Units)

Figure 37. Europe Interleukin Inhibitors for Psoriasis Revenue 2019-2024 (\$ millions)

Figure 38. Middle East & Africa Interleukin Inhibitors for Psoriasis Sales 2019-2024 (K Units)

Figure 39. Middle East & Africa Interleukin Inhibitors for Psoriasis Revenue 2019-2024 (\$ millions)

Figure 40. Americas Interleukin Inhibitors for Psoriasis Sales Market Share by Country in 2023

Figure 41. Americas Interleukin Inhibitors for Psoriasis Revenue Market Share by Country (2019-2024)

Figure 42. Americas Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2019-2024)

Figure 43. Americas Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2019-2024)

Figure 44. United States Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 45. Canada Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 46. Mexico Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 47. Brazil Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 48. APAC Interleukin Inhibitors for Psoriasis Sales Market Share by Region in 2023

Figure 49. APAC Interleukin Inhibitors for Psoriasis Revenue Market Share by Region (2019-2024)

Figure 50. APAC Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2019-2024)

Figure 51. APAC Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2019-2024)

Figure 52. China Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 53. Japan Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$

millions)

Figure 54. South Korea Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 55. Southeast Asia Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 56. India Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 57. Australia Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 58. ChinaTaiwan Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 59. Europe Interleukin Inhibitors for Psoriasis Sales Market Share by Country in 2023

Figure 60. Europe Interleukin Inhibitors for Psoriasis Revenue Market Share by Country (2019-2024)

Figure 61. Europe Interleukin Inhibitors for Psoriasis Sales Market Share byType (2019-2024)

Figure 62. Europe Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2019-2024)

Figure 63. Germany Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 64. France Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 65. UK Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 66. Italy Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 67. Russia Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 68. Middle East & Africa Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2019-2024)

Figure 69. Middle East & Africa Interleukin Inhibitors for Psoriasis Sales Market Share byType (2019-2024)

Figure 70. Middle East & Africa Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2019-2024)

Figure 71. Egypt Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 72. South Africa Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 73. Israel Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 74. Turkey Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 75. GCC Countries Interleukin Inhibitors for Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 76. Manufacturing Cost Structure Analysis of Interleukin Inhibitors for Psoriasis in 2023

Figure 77. Manufacturing Process Analysis of Interleukin Inhibitors for Psoriasis

Figure 78. Industry Chain Structure of Interleukin Inhibitors for Psoriasis

Figure 79. Channels of Distribution

Figure 80. Global Interleukin Inhibitors for Psoriasis Sales MarketForecast by Region (2025-2030)

Figure 81. Global Interleukin Inhibitors for Psoriasis Revenue Market ShareForecast by Region (2025-2030)

Figure 82. Global Interleukin Inhibitors for Psoriasis Sales Market ShareForecast byType (2025-2030)

Figure 83. Global Interleukin Inhibitors for Psoriasis Revenue Market ShareForecast byType (2025-2030)

Figure 84. Global Interleukin Inhibitors for Psoriasis Sales Market ShareForecast by Application (2025-2030)

Figure 85. Global Interleukin Inhibitors for Psoriasis Revenue Market ShareForecast by Application (2025-2030)

I would like to order

Product name: Global Interleukin Inhibitors for Psoriasis Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GF1EC59DCD5BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF1EC59DCD5BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970